Clinical trials: System Sclerosis
Scleroderma, Systemic, Fibrosis; Skin
Western Sweden Systemic Sclerosis Project
The main aim of the project is to identify key-factors involved in the development and progression of Systemic Sclerosis (SSc), a chronic invalidating rheumatic disease characterized by high mortality and insufficient treatment…
- Conditions
- Scleroderma, Systemic, Fibrosis; Skin, Fibrosis Lung, Interstitial Lung Disease Due to Systemic Disease
- Trial name
- WESST (NCT07345052)
- Testing
- No Intervention: Observational Cohort
- Where
- Sweden
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Sahlgrenska University Hospital
Multiple Sclerosis (MS)
Sequential Natalizumab - Alemtuzumab Therapy in Patients With Relapsing Forms of Multiple Sclerosis
The purpose of this study is to determine if a sequential combination therapy of natalizumab and alemtuzumab induces peripheral tolerance and reduces the annualized relapse rate (ARR) in patients with relapsing-remitting multiple…
- Trial name
- SUPPRESS (NCT03135249)
- Testing
- Alemtuzumab
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- University of Texas Southwestern Medical Center
Multiple Sclerosis, Insulin Resistance
Insulin Resistance in Egyptian Patients With Multiple Sclerosis
The goal of this three-phase interventional study is to determine the prevalence of Insulin resistance in non-diabetic patients with multiple sclerosis in Egypt The main questions it aims to answer are: 1.
- Trial name
- IR-MS (NCT06017726)
- Testing
- treatment of insulin resistance with appropriate modality according to each patient
- Volunteers
- 100 people
- Sponsor
- Assiut University
Progressive Multiple Sclerosis
Telerehabilitation in Progressive Multiple Sclerosis
Multiple sclerosis (MS) is a highly disabling chronic, inflammatory, demyelinating disease of the Central Nervous System (CNS). Significant progress has been made during the past three decades in managing the relapsing-remitting…
- Trial name
- NCT06485115
- Testing
- Digital Telerehabilitation (Euleria Home), Conventional therapy
- Where
- Italy
- Volunteers
- 78 people
- Sponsor
- Universita di Verona
Amyotrophic Lateral Sclerosis
Frequency of SOD1 and C9orf72 Gene Mutations in French ALS
The purpose of the study is to determine the frequency of mutations in the C9orf72 and SOD1 genes in the incident population of ALS patients followed in the FILSLAN centres
- Trial name
- GENIALS (NCT04819555)
- Testing
- Blood
- Where
- 20 sites in France
- Volunteers
- 1,000 people
- Sponsor
- University Hospital, Tours
Amyotrophic Lateral Sclerosis (ALS)
Study on the Safety and Efficacy of RAG-21 in the Treatment of Amyotrophic Lateral Sclerosis Patients With FUS Gene Mutations
Amyotrophic lateral sclerosis (ALS) is a chronic progressive neurodegenerative disease that remains incurable, with limited existing therapies or drugs available. Familial ALS can be caused by mutations in various genes.
- Trial name
- RAG-21-FUS-ALS (NCT07080801)
- Testing
- RAG-21
- Volunteers
- 6 people
- Sponsor
- Beijing Tiantan Hospital
Multiple Sclerosis (MS) - Relapsing-remitting
Behavioral and Electrophysiological Evidence of the Modulation of Fatigue in RR-MS
To furnish behavioral and electrophysiological evidence of the possible modulation of fatigue in Multiple Sclerosis - relapsing remitting form, through a verbal placebo.
- Trial name
- Fatigue_SM (NCT07624812)
- Testing
- TENS therapy
- Where
- Italy
- Volunteers
- 36 people
- Sponsor
- Istituto Auxologico Italiano
ALS (Amyotrophic Lateral Sclerosis)
ALS Reversals - Lunasin Regimen
This is a 12-month, widely inclusive, largely virtual, single-center, open-label pilot trial utilizing a historical control group.
- Trial name
- NCT02709330
- Testing
- Lunasin Regimen, Historical control
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Richard Bedlack, M.D., Ph.D.
Multiple Sclerosis, Healthy Adult
Investigating Specific Gait Patterns in Individuals Living With Multiple Sclerosis
The study aims to investigate specific ambulation patterns characteristic of the quality of gait in people with MS (pwMS)
- Trial name
- GAIT-MS (NCT07388992)
- Where
- France
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- SYSNAV
Multiple Sclerosis
US PROmyBETAapp2.0: A Study to Learn More About the Medication Usage and Patient Reported Outcomes Via the myBETAapp in Medical Care of Patients With Multiple Sclerosis Treated With BETASERON Using BETACONNECT Autoinjector
In this study researchers want to learn more about the medication usage behavior among multiple sclerosis (MS) patients treated with BETASERON using the myBETAapp.
- Trial name
- NCT04356339
- Testing
- Interferon-beta-1b (BETASERON, BAY 86-5046)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Bayer
Multiple Sclerosis
A Multi-center, Multi-regional Observational Study to Test the Responsiveness of the Validated MusiQoL (Multiple Sclerosis International Quality of Life Questionnaire) Instrument to EDSS Status Changes in Any Form of Multiple Sclerosis (MS) in Patients With or Without Treatment
This is a multi-center, multi-regional observational,24 month study. Health-related quality of life data from the MusiQoL instrument and SF-36 instrument will be collected at baseline, M6, M12, M18 and M24 in patients with MS.
- Trial name
- MusiQoL (NCT00702065)
- Where
- 30 sites in United States, Argentina and 10 more
- Volunteers
- 599 people
- Sponsor
- EMD Serono
Multiple Sclerosis, Depression
Depression and Facial Identity Recognition Abilities in Patients With Multiple Sclerosis
Cognitive and emotional disorders are often encountered in multiple sclerosis (MS) cases: depressive and bipolar disorders are twice as frequent as in general population.
- Trial name
- SepDep (NCT02468765)
- Testing
- Neuropsychological and emotional evaluation with monitoring
- Where
- France
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Lille Catholic University
Multiple Sclerosis
Duloxetine for Multiple Sclerosis Pain
This study is designed to primarily assess the efficacy and safety of duloxetine 60-120 mg once daily (QD) compared with placebo on the reduction of pain severity in participants with central neuropathic pain due to Multiple…
- Trial name
- NCT00755807
- Testing
- Duloxetine Hydrochloride (HCI)
- Where
- 22 sites in United States, Belgium and 2 more
- Volunteers
- 239 people
- Sponsor
- Eli Lilly and Company
Multiple Sclerosis
Determine Impact of Multiple NAb Tests on Treatment Compared to Usual Care of MS Patients on High-dose IFN Therapy
An observational study to determine the impact of multiple neutralizing antibody (NAb) tests on treatment patterns compared to the usual care of MS patients receiving high-dose IFN therapy.
- Trial name
- NCT00336557
- Testing
- NAbs testing
- Where
- 49 sites in United States
- Volunteers
- 1,230 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Relapsing-remitting Multiple Sclerosis, Active Secondary Progressive Multiple Sclerosis
Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg Pen
This study was an uncontrolled, central registration system, open-label, multicenter observational study in patients using Kesimpta for the labeled indication.
- Trial name
- NCT04940065
- Testing
- Kesimpta
- Where
- 103 sites in Japan
- Volunteers
- 367 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
Addition of Belimumab to B-cell Depletion in Relapsing-remitting Multiple Sclerosis
Multiple sclerosis is the most common inflammatory disease of the central nervous system and a common cause of disability in young adults.
- Trial name
- NCT04767698
- Testing
- Belimumab, Short-course Ocrelizumab, Continued Ocrelizumab
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Johns Hopkins University
Relapsing Remitting Multiple Sclerosis
PROFILE - Evaluation of QoL and PRO Outcomes in Patients Taking Fingolimod
Multi centre, prospective, non interventional study in 200-240 UK relapsing remitting multiple sclerosis patients. Patients will complete questionnaires at baseline, 3, 6 and 12 months.
- Trial name
- PROFILE (NCT02335892)
- Where
- 14 sites in United Kingdom
- Volunteers
- 114 people
- Sponsor
- Novartis Pharmaceuticals
Relapsing Remitting Multiple Sclerosis, Fatigue
Correlation Between Daily Physical Activity and Disability, Fatigue, Cognition and Quality of Life in MS Patients
The main purpose of the study is to assess the fatigue, cognition, quality of life and disability correlation to MS-patients daily physical activity.
- Conditions
- Relapsing Remitting Multiple Sclerosis, Fatigue, Quality of Life, Physical Activity
- Trial name
- PAMS (NCT04115930)
- Testing
- Physical Activity measurement:
- Where
- 4 sites in Finland
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- University of Eastern Finland
Multiple Sclerosis
Prolonged-release Fampridine as Adjunct Therapy to Active Motor Training in MS Patients
Phase 4, single center, double-blind, placebo-controlled study. Fifty (50) patients with MacDonald criteria (2005) multiple sclerosis will undergo active motor training as per the NeuroGym protocol, consisting of 3 sessions of 1…
- Trial name
- NCT02146534
- Testing
- extended release fampridine
- Where
- Canada
- Volunteers
- 44 people
- Sponsor
- Clinique Neuro-Outaouais
Spasticity, Multiple Sclerosis
One Year Extension Study To Protocol C2/5/TZ:MS-05
Open label, one year extension study to evaluate the clinical efficacy and safety of 12 mg sublingual tizanidine administered once nightly in MS patients who successfully completed Phase I/II protocol C2/5/TZ:MS-05 at the Tel…
- Trial name
- NCT00464958
- Testing
- sublingual tizanidine 12 mg
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- Teva GTC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.